This bill amends the Controlled Substances Act to update how the federal government classifies and regulates drugs by incorporating modern medical and scientific understanding. The legislation adds detailed definitions for key terms like "accepted medical use," "dependence liability," "abuse," and "misuse" to replace outdated language and reflect current medical practices. It also clarifies that the Attorney General must defer to the Secretary of Health and Human Services' scientific evaluation when deciding whether to add, remove, or reclassify drugs, and requires that scheduling decisions consider both potential harms and benefits to society while preserving legitimate medical access. The bill affects pharmaceutical companies, medical researchers, healthcare practitioners, and regulatory agencies like the FDA and DEA. No specific funding or implementation timeline is included in the text provided.